Kristie L. Kahl

The American Lung Association’s chief medical officer discusses e-cigarette use and answers common questions surrounding this increasing epidemic.

Here is a list of the recent trial initiations that occurred within the cancer space in August.

The US Preventive Services Task Force now recommends for genetic counseling and testing for survivors of certain cancer types, but many at high-risk for the disease are left off the list.

CURE spoke with an expert to discuss financial toxicity and the important of seeking support after receiving a cancer diagnosis.

From celebrity news to a new partnership aimed to help patients and their caregivers, here’s what is making headlines in the cancer space this week.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Jason Mendelsohn, a stage 4 HPV-related throat cancer survivor who created a web site geared to raising awareness about HPV-related cancers.

Patients whose cancers have the NTRK gene fusion as well as those with ROS1-positive non-small cell lung cancer now have a second targeted therapy as a treatment option.

After almost a decade with no new treatments, Inrebic offers patients with myelofibrosis new hope for the future.

Following its announcement of covering chimeric antigen receptor-T cell therapy nationwide, the Centers for Medicare and Medicaid Services has now made this highly-priced, but life-saving, treatment available to many who would not otherwise have access to it at their cancer centers.

The Food and Drug Administration approved Inrebic as the first new treatment in nearly a decade for patients with myelofibrosis.

In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with a melanoma survivor about the importance of community and human connection to build hope after a cancer diagnosis.

Those with a first-degree relative diagnosed with certain blood cancers may be at an increased risk for developing the disease themselves.

Given the hardships cancer can have on an individual and their loved ones, support groups can be a useful tool in navigating the new normal.

A registered dietician discussed the importance of maintaining one’s weight while going through treatment for mesothelioma.

From hereditary cancer risk among twins to study findings in squamous cell carcinoma, here’s what is making headlines in the cancer space this week.

Although survival among AYAs with cancer has improved over recent decades, disparities within the severity of stage, race/ethnicity and socioeconomic status are still just as prevalent.

In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with Allyn Rose, the first woman who had undergone a mastectomy to be featured by Sports Illustrated, about her family history with cancer and her advocacy work with the AIRs Foundation.

The Food and Drug Administration’s approval of Keytruda in recurrent locally advanced or metastatic esophageal squamous cell carcinoma led to new progress for this patient population.

A slower walking pace among older adults with blood cancer can be a sign of frailty – which could be useful to know when tailoring one’s care to increase survival and lower hospitalizations.

The Food and Drug Administration approved Turalio to treat patients diagnosed with a group of rare, benign tumors.

In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with a caregiver about support for others taking care of a loved one with cancer through a letter she wrote to her younger self.

Following the Food and Drug Administration’s approval of Nubeqa, men with non-metastatic castration-resistant prostate cancer now have an earlier more precise treatment option.

The Food and Drug Administration has approved Keytruda for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus in certain patients.

The Food and Drug Administration granted a priority review to Nubeqa for the treatment of men with non-metastatic castration-resistant prostate cancer.

Here is a list of the recent trial initiations that occurred within the cancer space in July.

CURE® spoke with one expert about the various treatment options and current clinical trials available to patients with mesothelioma, as well as what they have to look forward to in the future.

CURE spoke with one expert about mesothelioma symptoms that patients can be on the lookout for, as well as how to be knowledgeable about certain risk factors.

In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with ex-NFL kicker Rolf Benirschke about being a grateful patient and how one can choose to be the victim or the victor in their diagnosis.

The Food and Drug Administration granted a priority review to a new drug application for the accelerated approval of tazemetostat to treat metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.

With the Food and Drug Administration’s approval of Ruxience, a biosimilar to Rituxan, patients with certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia may have improved access to a more affordable treatment option.